AQR Capital Management LLC Lowers Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AQR Capital Management LLC reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 533,682 shares of the specialty pharmaceutical company's stock after selling 19,883 shares during the quarter. AQR Capital Management LLC owned about 0.88% of Jazz Pharmaceuticals worth $65,723,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $25,000. Quadrant Capital Group LLC grew its position in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the period. CoreFirst Bank & Trust bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Allianz SE bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $29,000. Finally, Jones Financial Companies Lllp lifted its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,140 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares of the company's stock, valued at approximately $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the sale, the chief executive officer now directly owns 440,307 shares of the company's stock, valued at $54,487,991.25. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,236 shares of company stock worth $3,839,840 in the last quarter. 4.20% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. HC Wainwright lifted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. Morgan Stanley reiterated an "overweight" rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Finally, Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $187.71.

Jazz Pharmaceuticals Stock Performance

JAZZ stock traded down $1.85 during midday trading on Monday, reaching $118.20. 936,526 shares of the company's stock traded hands, compared to its average volume of 805,960. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a 50-day moving average price of $122.63 and a two-hundred day moving average price of $122.52. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $7.28 billion, a PE ratio of 16.71, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.